Catalyst Clinical Research, based in North Carolina, has acquired Genpro Research, a Contract Research Organization (CRO), to expand its global presence.

With this acquisition, Catalyst gains Genpro’s sites and staff in the United States, India, and Ireland. Genpro is well-known for its expertise in biometrics, medical writing, real-world evidence, and AI-enabled automation product development.

While the financial details of the deal were not disclosed, Catalyst stated in a press release on July 20 that Genpro’s CEO, Sachin Marulkar, M.D., and the management team will continue to lead the operation.

This acquisition is part of a trend of consolidation in the CRO industry, with many companies announcing similar deals in recent months. NAMSA, Alcanza, and Signant Health are among the other CROs that have made acquisitions in July. Additionally, Labcorp’s CRO spinoff, Fortrea, was launched over the Independence Day weekend.